Publications ORBi OA
Clairance plasmatique des cytokines IL6 et IL10 par hémofiltration avec un filtre à larges pores dans un modèle porcin de choc septique.
Delanaye, Pierre ; Lambermont, Bernard ; Dogné, Jean-Michel et al
in Réanimation (2006), 15(S1), 7Detailed reference viewed: 65 (20 ULg)
Speech discrimination and intelligibility: outcome of deaf children fitted with hearing aids or cochlear implants.
Lejeune, Brigitte ;
in B-ENT (2006), 2(2), 63-68
We retrospectively studied outcome of a sample of 36 congenitally deaf children who were fitted with either a conventional hearing aid or a cochlear implant and who received many years of audio-phonatory ... [more ▼]
We retrospectively studied outcome of a sample of 36 congenitally deaf children who were fitted with either a conventional hearing aid or a cochlear implant and who received many years of audio-phonatory training.To rate auditory capacity and speech intelligibility, we used commonly used metrics: CAP and SIR. At the end of the 5-Years period, CAP and SIR scores of cochlear implant children are significantly higher than those of conventional hearing aid children. This study is one of few that evaluates outcome of conventional hearing aid and cochlear implant fitting with age matched congenitally deaf children anno 2000. [less ▲]Detailed reference viewed: 166 (11 ULg)
Le risque de préjudice grave difficilement réparable en matière de nomination ou de promotion dans la fonction publique
in Revue de Jurisprudence de Liège, Mons et Bruxelles (2006), (1), 24-42Detailed reference viewed: 216 (5 ULg)
Influence of the matrix on analyte fragmentation in atmospheric pressure MALDI
; ; Rosu, Frédéric et al
in Journal of the American Society for Mass Spectrometry (2006), 17(7), 1005-1013
In this paper, we report the measurement of the degree of analyte fragmentation in AP-MALDI as a function of the matrix and of the laser fluence. The analytes include p-OCH3-benzylpyridinium, three ... [more ▼]
In this paper, we report the measurement of the degree of analyte fragmentation in AP-MALDI as a function of the matrix and of the laser fluence. The analytes include p-OCH3-benzylpyridinium, three peptides containing the sequence EEPP (which cleave very efficiently at the E-P site), and three deoxynucleosides (dA, dG, and dC), which lose the neutral sugar to give the protonated base. We found that the matrix hardness/softness was consistent when comparing the analytes, with a consensus ranking from hardest to softest: CHCA >> DHB > SA approximate to THAP > ATT > HPA. However, the exact ranking can be fluence-dependent, for example between ATT and HPA. Our goal here was to provide the scientific community with a detailed dataset that can be used to compare with theoretical predictions. We tried to correlate the consensus ranking with different matrix properties: sublimation or decomposition temperature (determined using thermogravimetry), analyte initial velocity, and matrix proton affinity. The best correlation was found with the matrix proton affinity. [less ▲]Detailed reference viewed: 49 (1 ULg)
Transfusions after nonmyeloablative or reduced-intensity conditioning regimens.
Baron, Frédéric ; ; Beguin, Yves
in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2006), 20(12), 2081-6Detailed reference viewed: 9 (0 ULg)
Increased iron absorption during autologous blood donation supported by recombinant human erythropoietin therapy.
Bovy, Christophe ; Baudoux, Etienne ; Salmon, Jean et al
in Transfusion (2006), 46(9), 1616-23
BACKGROUND: Recombinant human erythropoietin (rHuEPO) therapy improves the success of autologous blood (AB) donation programs before elective surgery. The aim of this study was to evaluate iron absorption ... [more ▼]
BACKGROUND: Recombinant human erythropoietin (rHuEPO) therapy improves the success of autologous blood (AB) donation programs before elective surgery. The aim of this study was to evaluate iron absorption during an AB donation program with or without rHuEPO. STUDY DESIGN AND METHODS: Thirty-two patients were randomly assigned among placebo (Group 1) or 300 (Group 2) or 600 UI per kg rHuEPO (Group 3) on the first, second, and third donation visits. All patients also received daily oral iron (200 mg Fe(+)). RESULTS: The number of units collected in Group 3 was higher than in Group 1 (4.6 +/- 0.5 vs. 3.6 +/- 0.8 units; p < 0.01). Red blood cell (RBC) production increased in a rHuEPO dose-dependent manner. With rHuEPO, the RBC volume collected per unit presented a lower decrease with number of donated units than with placebo and was similar to that of homologous blood units. Storage iron did not influence the number of units collected, whereas circulating mobilizable iron was the limiting factor. Oral iron absorption increased in a rHuEPO dose-dependent manner (12-fold with 600 UI/kg rHuEPO) and was proportional to erythropoietic activity. CONCLUSION: rHuEPO does not only improve the number of AB units collected but also their quality. Storage iron cannot meet marrow iron requirements, but rHuEPO strongly increased oral iron absorption in a dose-dependent fashion through stimulation of erythropoietic activity. [less ▲]Detailed reference viewed: 24 (0 ULg)
Iron and the anaemia of chronic disease: a review and strategic recommendations.
; ; et al
in Current Medical Research & Opinion (2006), 22(4), 731-7
BACKGROUND: The incidence of anaemia is high in many chronic conditions, yet it often receives little attention. SCOPE/METHODS: A panel of international experts with experience in haematology, nephrology ... [more ▼]
BACKGROUND: The incidence of anaemia is high in many chronic conditions, yet it often receives little attention. SCOPE/METHODS: A panel of international experts with experience in haematology, nephrology, oncology, rheumatology and pharmacy was convened to prepare strategic guidelines. A focused literature search was conducted after key issues had been identified. A series of recommendations was agreed, backed, wherever possible, by published evidence which is included in the annotations. RECOMMENDATIONS: Anaemia is a critical issue for patients with chronic diseases. Healthcare professionals need to recognise that anaemia is a frequent companion of cancer and chronic conditions such as rheumatoid arthritis and heart failure. It reduces patients' quality of life and can increase morbidity and mortality. Anaemia should be considered as a disordered process in which the rate of red cell production fails to match the rate of destruction which leads eventually to a reduction in haemoglobin concentration; this process is common to all chronic anaemias. The aim of anaemia management should be to restore patient functionality and quality of life by restoring effective red cell production. Blood transfusion can elevate haemoglobin concentration in the short term but does nothing to address the underlying disorder; red cell transfusion is, therefore, not an appropriate treatment for chronic anaemia. Patients with anaemia of chronic disease may benefit from iron therapy and/or erythropoiesis stimulating agents (ESAs). Intravenous iron should be considered since this can be given safely to patients with chronic diseases while intramuscular iron causes unacceptable adverse effects and oral iron has limited efficacy in chronic anaemia. CONCLUSION: The management of anaemia calls for the development of a specialist service together with education of all healthcare professionals and transfer of skills from areas of good practice. Improvement in the management of anaemia requires a fundamental change of attitude from healthcare professionals. [less ▲]Detailed reference viewed: 23 (1 ULg)
Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation.
; Frere, Pascale ; et al
in Experimental hematology (2006), 34(3), 382-8
In order to assess the effect of Pegfilgrastim on the duration of neutropenia and clinical outcome of patients after autologous peripheral blood stem cell (PBSC) transplantation, we compared 20 ... [more ▼]
In order to assess the effect of Pegfilgrastim on the duration of neutropenia and clinical outcome of patients after autologous peripheral blood stem cell (PBSC) transplantation, we compared 20 consecutive patients with lymphoma or multiple myeloma receiving a single 6-mg dose of Pegfilgrastim on day 1 posttransplant to an historical control group of 60 patients receiving daily Filgrastim 5 microg/kg starting on day 1 posttransplant. The duration of neutropenia was similar in the Pegfilgrastim group compared with the control group. There were no differences in time to neutrophil, erythroid, or platelet engraftment nor in the incidence of fever and infections. The duration of antibiotic therapy, transfusion support, and time to hospital discharge were similar in the two groups. However, after initial hematopoietic reconstitution, we observed significantly higher values of lymphocytes (e.g., 1,660+/-1,000 versus 970+/-460 on day 80, p=0.0002), neutrophils (e.g., 3,880+/-2,030 versus 2,420+/-1,500 on day 25, p=0.0004), reticulocytes (e.g., 148,160+/-90,590 versus 87,140+/-65,920 on day 25, p<0.0001), and platelets (e.g., 210,700+/-116,090 versus 150,240+/-58,230 on day 55, p=0.0052) up to day 100 in the Pegfilgrastim group compared with the Filgrastim group. These observations had no impact on clinical outcome of the patients after day 30 due to the low incidence of infectious events after engraftment in autologous PBSC transplantation. We conclude that the effect of Pegfilgrastim administrated on day 1 posttransplant is comparable to that of daily Filgrastim on initial hematopoietic reconstitution. The possibly superior effect of Pegfilgrastim on cell counts we observed after initial engraftment should be further tested in a prospective randomized trial. [less ▲]Detailed reference viewed: 33 (1 ULg)
Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen.
Frere, Pascale ; Baron, Frédéric ; Bonnet, Christophe et al
in Bone Marrow Transplantation (2006), 37(4), 411-8
Hematopoietic cell transplantation (HCT) following nonmyeloablative conditioning (NMSCT) may be associated with a reduced risk of infection compared to standard allogeneic HCT. We retrospectively analyzed ... [more ▼]
Hematopoietic cell transplantation (HCT) following nonmyeloablative conditioning (NMSCT) may be associated with a reduced risk of infection compared to standard allogeneic HCT. We retrospectively analyzed incidence and risk factors of infection in 62 patients undergoing NMSCT with low-dose TBI +/- fludarabine and postgrafting CsA and MMF. The proportion of patients with any infection was 77%, but the majority of infectious events occurred beyond day 30. Donor other than sibling, older age, early disease and male gender were significant risk factors. The incidence of bacteremia was 55% at 1 year and the number of bacteremic episodes was 0.9 per patient (0.08 before day 30). The risk of bacteremia increased with older age and the use of a donor other than an HLA-identical sibling, but not with neutropenia. The incidence of infections other than bacteremia correlated with the use of corticosteroids. The risk of CMV infection increased with high-risk CMV serology, and risk of CMV disease with high-risk CMV serology, older age, first transplantation and a diagnosis of lymphoma. In conclusion, after NMSCT, infections are not frequent in the first 30 days post transplant but careful long-term monitoring is necessary thereafter. [less ▲]Detailed reference viewed: 66 (5 ULg)
Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response.
; Baron, Frédéric ; Willems, Evelyne et al
in Experimental hematology (2006), 34(7), 841-50
PURPOSE: After allogeneic hematopoietic stem cell transplantation with nonmyeloablative conditioning (NMHCT), many patients experience prolonged anemia and require red blood cell (RBC) transfusions. We ... [more ▼]
PURPOSE: After allogeneic hematopoietic stem cell transplantation with nonmyeloablative conditioning (NMHCT), many patients experience prolonged anemia and require red blood cell (RBC) transfusions. We enrolled 60 consecutive patients undergoing NMHCT in a phase II trial to determine the optimal utilization of recombinant human erythropoietin (rHuEPO) therapy in this setting. PATIENTS AND METHODS: The first 14 NMHCT recipients did not receive rHuEPO (control group). Nineteen patients were scheduled to start rHuEPO on day 0 (EPO group 2) and 27 patients on day 28 after the transplant (EPO group 1). RHuEPO was administered subcutaneously once weekly at a dose of 500 U/kg/wk with the aim of achieving hemoglobin (Hb) levels of 13 g/dL. The 3 groups were well balanced for major characteristics. RESULTS: During the first month (p < 0.0001) as well as days 30 to 100 (p < 0.0001) and days 100 to 180 (p < 0.0001), Hb values were higher in patients receiving rHuEPO compared to those not receiving it. However, transfusion requirements were significantly decreased only in the first month in EPO group 2 (p = 0.0169). T-cell chimerism above 60% on day 42 was the best predictor of Hb response (p < 0.0001) or Hb correction (p = 0.0217), but myeloid chimerism above 90% also predicted for Hb response (p = 0.0069). Hb response was also decreased in patients receiving CD8-depleted grafts and increased in the few patients not receiving TBI, but only in univariate analysis. CONCLUSIONS: Anemia after NMHCT is sensitive to rHuEPO therapy, but less so than after conventional allogeneic HCT. RHuEPO decreases transfusion requirements only in the first 30 days posttransplant. T-cell chimerism below 60% on day 42 impaired Hb response, suggesting possible inhibition of donor erythropoiesis by residual recipient lymphocytes. A prospective randomized trial should be performed with rHuEPO starting on the day of transplantation to assess its clinical benefit in terms of transfusion requirements and quality of life. [less ▲]Detailed reference viewed: 53 (4 ULg)
Sur les difficultés d'application du standstill dans la passation des marchés publics
Lewalle, Paul ; Donnay, Luc
in Revue de la Faculté de Droit de l'Université de Liège (2006), 1-2Detailed reference viewed: 85 (15 ULg)
Boules et autres masses". Prise en charge rationnelle des tumeurs des tissus mous."
Kurth, William ; Gillet, Philippe
in Revue Médicale de Liège (2006), 61(11), 763-70
Patients with soft-tissue tumours usually consult for a mass at the level of an extremity or the torso. This article aims to help the general practitioner and the general surgeon in the standardized setup ... [more ▼]
Patients with soft-tissue tumours usually consult for a mass at the level of an extremity or the torso. This article aims to help the general practitioner and the general surgeon in the standardized setup of these tumours. The epidemiology, clinical presentation and evaluation as well as the useful exams to be performed, including biopsy, are developped, in order to obtain rational principles for the diagnostic setup and surgical decision-making. [less ▲]Detailed reference viewed: 139 (11 ULg)
Etude clinique du mois. L'etude DREAM: prevention du diabete de type 2 par le ramipiril et/ou la rosiglitazone chez les personnes dysglycemiques sans maladie cardio-vasculaire.
in Revue Médicale de Liège (2006), 61(10), 728-32
DREAM ("Diabetes Reduction Assessment with ramipril and rosiglitazone Medication") is a double-blind randomised placebo-controlled clinical trial with a 2-by-2 factorial design aiming to study the effects ... [more ▼]
DREAM ("Diabetes Reduction Assessment with ramipril and rosiglitazone Medication") is a double-blind randomised placebo-controlled clinical trial with a 2-by-2 factorial design aiming to study the effects of an ACE inhibitor (ramipril 15 mg/day) and/or a thiazolidinedione (rosiglitazone 8 mg/day) on the development of diabetes or death (primary outcome) and on the regression to normoglycaemia (secondary outcome) in 5269 adults aged 30 years or more with impaired fasting glucose and/or impaired glucose tolerance, and no previous cardiovascular disease. There was no statistical evidence of an interaction between the ramipril and the rosiglitazone arms. After a mean follow up of 3 years, the use of ramipril does not significantly reduce the incidence of diabetes or death but does significantly increase regression to normoglycaemia. In contrast, the treatment with rosiglitazone reduces by almost 60% the incidence of type 2 diabetes and increases the likelihood (+70%) of regression to normoglycaemia. Whether it is a true prevention effect or simply a treatment effect remains to be determined when participants will be retested after a washout period. Cardiovascular event rates were rather low and much the same in all treatment groups, except a higher rate of heart failure in the rosiglitazone group. These results suggest that the routine inhibition of the renin-angiotensin system for the express purpose of preventing diabetes is not indicated in individuals not at high risk for cardiovascular disease and appear to confirm the promises of the glitazone use in the very early stage of the natural history of type 2 diabetes. [less ▲]Detailed reference viewed: 97 (1 ULg)
Le syndrome metabolique: physiopathologie et traitement
in Athérosclérose, athérothrombose (2006)Detailed reference viewed: 152 (3 ULg)
Note on singular optima in laminate design problems
; Duysinx, Pierre
in Structural and Multidisciplinary Optimization (2006), 31(2), 156-159
This paper studies the design of laminates subject to restrictions on the ply strength. The minimum weight design is considered. It is shown that this formulation includes singular optima, which are ... [more ▼]
This paper studies the design of laminates subject to restrictions on the ply strength. The minimum weight design is considered. It is shown that this formulation includes singular optima, which are similar to the ones observed in topology optimization including local stress constraints. In laminate design, these singular optima are linked to the removal of 'zero thickness' plies from the stacking sequence. It is shown how the fiber orientation variables can circumvent the singularity by relaxing the strength constraints related to such vanishing plies. This demonstrates the key role of fiber orientations in the optimization of laminates and the need for their efficient treatment as design variables. [less ▲]Detailed reference viewed: 50 (3 ULg)
Generalized shape optimization with X-FEM and Level Set description applied to stress constrained structures
Van Miegroet, Laurent ; ; Duysinx, Pierre et al
Conference (2006)Detailed reference viewed: 40 (3 ULg)
Risico's verbonden aan Enterobacter sakazakii in zuigelingenvoeding.
; ; Daube, Georges et al
in Tijdschrift voor Geneeskunde (2006), 62
Enterobacter sakazakii is een zeldzame maar bekende oorzaak van neonatale sepsis en een ernstig verlopende vorm van meningitis met een mortaliteit van 10 tot 80 %. Verschillende infecties zijn in verband ... [more ▼]
Enterobacter sakazakii is een zeldzame maar bekende oorzaak van neonatale sepsis en een ernstig verlopende vorm van meningitis met een mortaliteit van 10 tot 80 %. Verschillende infecties zijn in verband gebracht met de consumptie van zuigelingenvoeding. In opdracht van het FAVV (Federaal Agentschap voor de Veiligheid van de Voedselketen) werd een studie verricht met betrekking tot het contaminatieniveau, de voorwaarden voor groei en overleving en de risico’s op infectie van E. sakazakii in zuigelingenvoeding. Dit met het oog op het formuleren van richtlijnen omtrent de voorwaarden voor bereiding, bewaring en toediening van zuigelingenvoeding . Melkpoeder is niet absoluut steriel is en een mogelijks lage besmetting (productienorm: < 1 kve per 10g) met E. sakazakii kan aanwezig zijn. Bij bereiding moeten de nodige hygiënische maatregelen in acht worden genomen. Er wordt aanbevolen de bereide zuigelingenvoeding binnen maximaal 2h te koelen tot 5°C en een maximum bewaartijd van 24h te respecteren. Opwarmen van het gerehydrateerd melkpoeder tot 37°C, warm houden en toedienen van bereide zuigelingenvoeding is een totaalproces dat maximum 1h in beslag mag nemen opdat er zich een voldoende marge tussen het aantal E. sakazakii cellen en de infectieve dosis zou bevinden. Door opvolgen van deze richtlijnen kan het risico op neonatale E. sakazakiiinfecties sterk gereduceerd worden. [less ▲]Detailed reference viewed: 105 (4 ULg)
Inhibiteurs de l'enzyme de conversion de l'angiotensine ou antagonistes des récepteurs de l'angiotensine 2 en pathologie cardio-vasculaire et néphrologique : que nous dit l'Evidence Based Medicine?
Krzesinski, Jean-Marie ; Montrieux, Christian ; Scheen, André
in Revue Médicale de Liège (2006), 61(5-6), 414-422
Inhibitors of the renin-angiotensin system have proved their great value in secondary prevention trials for cardiovascular or renal complications. In favour of the preferred use of angiotensin receptor ... [more ▼]
Inhibitors of the renin-angiotensin system have proved their great value in secondary prevention trials for cardiovascular or renal complications. In favour of the preferred use of angiotensin receptor antagonists stand their excellent tolerance and the possible therapeutic escape seen with angiotensin converting enzyme inhibitors. For the preferential use of the latter, the arguments are the absence of a real proof of any superiority of the angiotensin receptor blockers and their higher cost. The wisdom is to initially use angiotensin converting enzyme inhibitors in secondary prevention excepted when they are not well tolerated. The large ONTARGET cardiovascular prevention trial should help solve this controversy. [less ▲]Detailed reference viewed: 309 (4 ULg)
Revue de la Faculté de droit de l'Université de Liège : Tables décennales 1996-2005
Bruyère, Aurélie ; Thys, Laurence
in Revue de la Faculté de droit de l'Université de Liège (2006)Detailed reference viewed: 62 (30 ULg)